Russell Investments Group Ltd. Has $20.43 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Russell Investments Group Ltd. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 88,118 shares of the medical research company's stock after selling 15,691 shares during the quarter. Russell Investments Group Ltd.'s holdings in IQVIA were worth $20,425,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Commonwealth Equity Services LLC increased its position in shares of IQVIA by 3.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 20,753 shares of the medical research company's stock valued at $4,083,000 after purchasing an additional 726 shares during the last quarter. Pinnacle Associates Ltd. lifted its holdings in IQVIA by 65.6% during the 3rd quarter. Pinnacle Associates Ltd. now owns 1,678 shares of the medical research company's stock worth $330,000 after buying an additional 665 shares during the last quarter. Stratos Wealth Partners LTD. boosted its position in shares of IQVIA by 6.4% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 6,739 shares of the medical research company's stock worth $1,326,000 after acquiring an additional 404 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its holdings in shares of IQVIA by 1.4% in the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 89,900 shares of the medical research company's stock valued at $17,688,000 after acquiring an additional 1,200 shares during the last quarter. Finally, Brown Advisory Inc. lifted its stake in IQVIA by 11.8% during the third quarter. Brown Advisory Inc. now owns 1,688 shares of the medical research company's stock worth $332,000 after purchasing an additional 178 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

NYSE IQV traded up $1.25 during trading hours on Friday, hitting $223.39. 1,052,927 shares of the stock were exchanged, compared to its average volume of 973,998. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The stock has a 50-day moving average of $244.56 and a 200 day moving average of $223.84. The company has a market cap of $40.55 billion, a price-to-earnings ratio of 30.64, a price-to-earnings-growth ratio of 2.25 and a beta of 1.52. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.82 by $0.02. The business had revenue of $3.87 billion during the quarter, compared to analysts' expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The company's quarterly revenue was up 3.5% compared to the same quarter last year. During the same period last year, the firm earned $2.54 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.12 earnings per share for the current year.

Insider Transactions at IQVIA

In related news, insider Ari Bousbib sold 31,678 shares of the firm's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Ari Bousbib sold 31,678 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company's stock, valued at approximately $199,610,278.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of the business's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the sale, the insider now owns 5,251 shares in the company, valued at $1,313,642.67. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock valued at $10,331,003 in the last ninety days. 1.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Leerink Partnrs reissued an "outperform" rating on shares of IQVIA in a report on Monday, February 26th. Truist Financial reduced their price target on shares of IQVIA from $297.00 to $292.00 and set a "buy" rating for the company in a research report on Friday. UBS Group lifted their target price on IQVIA from $240.00 to $300.00 and gave the stock a "buy" rating in a research report on Thursday, February 15th. Guggenheim cut IQVIA from a "buy" rating to a "neutral" rating in a research report on Thursday, February 15th. Finally, StockNews.com raised IQVIA from a "hold" rating to a "buy" rating in a research report on Friday, February 16th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average price target of $257.57.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.